Navigation Links
TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
Date:10/17/2007

BOSTON, Oct. 17 /PRNewswire/ -- TEI Biosciences Inc. announces the launch of its SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction product. TEI has received 510(k) clearance from the U.S. Food and Drug Administration to market SurgiMend for expanded use in plastic and reconstructive surgery, including breast reconstruction, and for tendon augmentation, in addition to the previously cleared hernia repair and muscle flap reinforcement indications.

"SurgiMend has been the biologic material of choice for many general, plastic, and trauma surgeons for their hernia repair and muscle flap reinforcement needs. With multiple indications, excellent handling and suturing characteristics, and a rapid hydration rate that saves valuable operating room time, SurgiMend has the potential to become the medical community's primary choice for soft tissue repair and reconstruction. In addition, SurgiMend provides an opportunity for hospitals to cover a broad range of applications with a single biologic device at a single price point," said Yiannis Monovoukas, Ph.D., TEI's Chairman, President, and CEO.

SurgiMend is an acellular, terminally sterilized biologic matrix derived from the dermis of fetal calves, one of the purest sources of collagen available. It is intrinsically strong yet soft and pliable when hydrated, and handles like natural tissue; it readily conforms to the surgical site and is easily sutured. SurgiMend is rich in Type III collagen, the active collagen found in developing and healing tissues. It is not artificially crosslinked and its biochemistry and microporosity facilitate rapid cell penetration, revascularization, and integration with host tissues. SurgiMend is available in multiple sizes, both large and small, and can be stored dry at room temperature for up to three years.

SurgiMend will be on display at the American Society of Plastic Surgeons meeting in Baltimore, MD, October 29-30, at booth # 145.

About TEI Biosciences

A Boston-based, privately-held, leading biomedical company, TEI Biosciences Inc. (http://www.teibio.com) has applied its expertise in regenerative medicine to develop and commercialize novel biologic products for a broad spectrum of soft tissue repair and reinforcement applications -- from dura, tendon, and hernia repair to wound management and plastic and reconstructive surgery.

TEI sells its products directly and through partnerships with some of the world's major medical device companies. In addition to SurgiMend, TEI's marketed products include:

PriMatrix(TM) for skin wound management;

Durepair(R) for cranial and spinal dura mater repair;

Xenform(TM) for pelvic floor reconstruction; and

TissueMend(R) for tendon augmentation.

For further information, please contact:

Yiannis Monovoukas, Ph.D.

ymonovoukas@teibio.com

or

Tony Russo, Ph.D.

Russo Partners, LLC

(212) 845-4251

tony.russo@russopartnersllc.com.


'/>"/>
SOURCE TEI Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... Pharma and biotech consulting firm ... Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 years ... than a decade with leading market research firm, GfK. He began his pharma ...
(Date:2/22/2017)... Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 ... ) today announced its financial results for the ... "Our annual 2016 financial results reflect continued ... earnings exceeded $700 million," said Martine Rothblatt, Ph.D., ... financial results strengthen our ability to develop and ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... and operational results for the three months ended December 31, ... -based life sciences and diagnostics company that develops and ... ... continue to build on the commercial milestones achieved in fiscal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex Biosciences announced ... automated benchtop system for collecting intact circulating tumor cells (CTCs) that are shed ... Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San Francisco). , The ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):